Hoag Memorial Hospital Presbyterian
40
6
8
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.0%
4 terminated/withdrawn out of 40 trials
83.3%
-3.2% vs industry average
3%
1 trials in Phase 3/4
5%
1 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (40)
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Role: collaborator
Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate
Role: lead
Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD
Role: collaborator
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Role: lead
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Role: collaborator
Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device
Role: collaborator
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
Role: lead
Safety Study of Pritumumab in Brain Cancer
Role: collaborator
Perioperative Mindfulness Proposal
Role: lead
PET MRI as a Staging Tool for Head and Neck Cancer
Role: lead
Pancreatic Cancer Early Detection Registry
Role: lead
Intraoperative Radiotherapy for Early Stage Breast Cancer
Role: lead
Study of Dotatate Imaging in Breast Cancer
Role: lead
18F-fluoroestradiol (FES) PET/CT for Breast Cancer
Role: lead
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Role: lead
GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients
Role: collaborator
U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
Role: lead
A Retrospective Trial to Evaluate the Micra Pacemaker
Role: lead
STS & ACC Foundation's Transcutaneous Valve Therapy (TVT) Registry Foundation's Transcutaneous Valve Therapy (TVT) Registry
Role: lead
Atrial Fibrillation Ablation Registry
Role: lead